Benjamin Kaffenberger
Chief Resident, PGY-3
Credentials: · ·
History
2024–PresentOhio State University Hospital
PGY-32024–Present
- 2002–2006
State University
Research
Review · Journal of the National Comprehensive Cancer Network · 2022 · 415 citations
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
Journal of the National Comprehensive Cancer Network · 2020 · 405 citations
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease
Journal of Clinical Investigation · 2014 · 164 citations
60 papers · 9 as a resident
51 papers · 1 as a resident
49 papers
- KF
21 papers
20 papers
20 papers
19 papers · 2 as a resident
19 papers · 7 as a resident
Grants
- 2026–2031
Severe Cutaneous Adverse Reaction (SCAR) Clinical Research Consortium (CRC)
National Institute of Allergy and Infectious Diseases · U54
Project lead · $351.6K · Vanderbilt University Medical Center
- 2025–2030
STRIVE: Short-Term Research in Immunology and Virology Experience
National Institute of Allergy and Infectious Diseases · T35
PI · $211.6K · Ohio State University
Clinical trials
- 2024–2025
Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum
Principal investigator · Withdrawn
Ohio State University
- 2022–2025
Role of Intermittent Fasting in Psoriasis and Psoriatic Arthritis
Principal investigator · Completed
Ohio State University
- 2017–2018
An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
Principal investigator · Completed · Phase 2
Ohio State University
- 2017–2030
The Ohio State University Dermatology Biorepository
Principal investigator · Recruiting
Ohio State University